Objectives: To elaborate the expression of MTA3 in colon cancer and correlation with prognosis as well as clinical index. Methods: We chose a colon cancer tissue microarray with follow-up information (containing 90 colon cancer specimens). Immunohistochemistry was applied to investigate the expression level of MTA3. The relationship between MTA3 expression and clinical index as well as the prognosis of colon cancer were statistically analyzed by SPSS software respectively. Results: MTA3 was specifically expressed in the nucleus of colon cancer tissue and para-carcinoma tissue, and there was a significant positive correlation between them (r=0.278, P=0.008). The clinical indexes correlation analysis showed that: the expression of MTA3 in colon cancer tissue was not correlated with clinical indexes (P>0.05); the expression of MTA3 in para-carcinoma tissue was significant positive correlated with M staging, clinical staging (r=0.264, P=0.013; r=0.222, P=0.039). Further survival analysis showed that the expression of MTA3 in colon cancer tissue was significant negative correlated with overall survival time of patients (35.7% VS 54.2%, P=0.030), and it was an independent predict factor (P=0.045); the expression of MTA3 in paracarcinoma tissue was not correlated with overall survival time (P=0.576). In addition, age, N staging and M staging were all independent predict factors of colon cancer patients, and they were significant negative correlated with prognosis (P<0.05). Conclusion: We hypothesized that: MTA3 was a clear oncogene in colon cancer. There may be multiple genes involve in the cancer promoting gene network of MTA3 in both cancer tissue and para-carcinoma tissue, they all increased the migration ability of cancer cell and reduced the survival time of patients. Next step, in order to further understand the molecular mechanism of MTA3 in colon cancer, we will carry out cytology research.